Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.

"Declarations Competing interestsChangsheng Ma has received honoraria from Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Boehringer Ingelheim, and Bayer for lecture presentations. Menno Huisman has received research grants from Dutch Healthcare Fund, Dutch Heart Foundation, Bayer Health Care, Pfizer-BMS, and Leo Pharma, and consulting fees from Boehringer Ingelheim, Bayer Health Care, and Pfizer-BMS, that have been contributed to the Leiden University Medical Center. Gregory Lip is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are received personally. Sabrina Marler and Guoze Feng are employees of Boehringer Ingelheim. Xiaoxia Liu reports no conflicts of interest. Ethics approval and consent to participateGLORIA-AF was approved by the respective institutional review board or independent ethics committees of participating institutions according to national and international regulations, and was conducted in accordance with the Declaration of Helsinki International Committee on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent. Consent for publicationNot applicable. Competing interests Changsheng Ma has received honoraria from Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Boehringer Ingelheim, and Bayer for lecture presentations. Menno Huisman has received research grants from Dutch Healthcare Fund, Dutch Heart Foundation, Bayer Health Care, Pfizer-BMS, and Leo Pharma, and consulting fees from Boehringer Ingelheim, Bayer Health Care, and Pfizer-BMS, that have been contributed to the Leiden University Medical Center. Gregory Lip is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are received personally. Sabrina Marler and Guoze Feng are employees of Boehringer Ingelheim. Xiaoxia Liu reports no conflicts of interest."

"Funding This study was supported by Boehringer Ingelheim."

"Trial registration ClinicalTrials.gov NCT01468701."